

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement

Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance

Writing Committee Members:	David R. Holmes, Jr, MD, FACC, <i>Chair</i> ,* Michael J. Mack, MD, FACC, <i>Vice Chair</i> , [†] Sanjay Kaul, MBBS, FACC, <i>Vice Chair</i> ,* Arvind Agnihotri, MD, [‡] Karen P. Alexander, MD, FACC,* Steven R. Bailey, MD, FACC, FSCAI, [§] John H. Calhoun, MD, [‡] Blase A. Carabello, MD, FACC,* Milind Y. Desai, MBBS, FACC, ^{,¶} Fred H. Edwards, MD, FACC, [†] Gary S. Francis, MD, FACC, [#] Timothy J. Gardner, MD, FACC, [†] A. Pieter Kappetein, MD, PhD,** Jane A. Linderbaum, MS, CNP, AACC,* Chirojit Mukherjee, MD, ^{††} Debabrata Mukherjee, MD, FACC,* Catherine M. Otto, MD, FACC,* Carlos E. Ruiz, MD, PhD, FACC, FSCAI, [§] Ralph L. Sacco, MD, MS, FAHA, ^{‡‡} Donnette Smith, ^{§§} and James D. Thomas, MD, FACC
ACCF Task Force Members:	Robert A. Harrington, MD, FACC, <i>Chair</i> , Deepak L. Bhatt, MD, MPH, FACC, <i>Vice Chair</i> , Victor A. Ferrari, MD, FACC, John D. Fisher, MD, FACC, Mario J. Garcia, MD, FACC, Timothy J. Gardner, MD, FACC, Federico Gentile, MD, FACC, Michael F. Gilson, MD, FACC, Adrian F. Hernandez, MD, FACC, Alice K. Jacobs, MD, FACC, Sanjay Kaul, MBBS, FACC, Jane A. Linderbaum, MS, CNP, AACC, David J. Moliterno, MD, FACC, and Howard H. Weitz, MD, FACC

 Supplemental material is available online.

*American College of Cardiology Foundation Representative; [†]Society of Thoracic Surgeons Representative; [‡]American Association for Thoracic Surgery Representative; [§]The Society for Cardiovascular Angiography and Interventions Representative; ^{||}Society of Cardiovascular Computed Tomography Representative; [¶]Society for Cardiovascular Magnetic Resonance Representative; ^{**}Heart Failure Society of America Representative; ^{**}European Association for Cardio-Thoracic Surgery Representative; ^{††}Society of Cardiovascular Anesthesiologists Representative; ^{‡‡}American Heart Association Representative; ^{§§}Mended Hearts Consumer Advocate, Patient Representative; ^{|||}American Society of Echocardiography Representative.

Author Recusals: Writing committee members are required to recuse themselves from voting on sections to which their specific relationship with industry and other entities may apply; see Appendix 1 for recusal information.

This document was approved by the American College of Cardiology Foundation (ACCF) Board of Trustees, American Association for Thoracic Surgery (AATS) Council, Society for Cardiovascular Angiography and Interventions (SCAI) Board of Directors, Society of Thoracic Surgeons (STS) Board of Directors in January 2012 and endorsed by the governing bodies of the American Heart Association (AHA) Science Advisory and Coordinating Committee, American Society of Echocardiography (ASE), European Association for Cardio-Thoracic Surgery (EACTS), Heart Failure Society of America (HFSA), Mended Hearts, Society of Cardiovascular Anesthesiologists (SCA), Society of Cardiac Computed Tomography (SCCT), and the Society for Cardiovascular Magnetic Resonance (SCMR) in January 2012. For the purpose of complete transparency, disclosure information for the ACCF Board of Trustees, the board of the convening organization of this document, is available at: <http://www.cardiosource.org/ACCF/About-ACCF/Leadership/Officers-and-Trustees.aspx>. ACCF board members with relevant relationships with industry to the document may review and comment on the document but may not vote on approval.

The American College of Cardiology Foundation requests that this document be cited as follows: Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoun JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. *J Thorac Cardiovasc Surg*. 2012;144:e29-84.

This article has been copublished in *Anesthesia and Analgesia*, the *Annals of Thoracic Surgery*, *Catheterization and Cardiovascular Interventions*, and the *Journal of the American College of Cardiology*.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (<http://www.cardiosource.org>), the American Association for Thoracic Surgery (<http://www.aats.org>), the Society for Cardiovascular Angiography and Interventions (<http://www.scai.org>), the Society of Thoracic Surgeons (<http://sts.org>), the American Society of Echocardiography (<http://www.asecho.org>), the Heart Failure Society of America (<http://www.hfso.org>), and Mended Hearts (<http://mendedhearts.org>). For copies of this document, please contact Elsevier Inc. Reprint Department, fax 212-633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at healthpermissions@elsevier.com.

0022-5223/\$36.00

Copyright © 2012 by American Association for Thoracic Surgery, the American College of Cardiology Foundation, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons

doi:10.1016/j.jtcvs.2012.03.001

Abbreviations and Acronyms

AR	= aortic regurgitation
AS	= aortic stenosis
AVA	= aortic valve area
AVR	= aortic valve replacement
CAD	= coronary artery disease
CMR	= cardiac magnetic resonance
COPD	= chronic obstructive pulmonary disease
CT	= computed tomography
EF	= ejection fraction
EOA	= effective orifice area
EuroSCORE	= European system for cardiac operative risk evaluation
LV	= left ventricular
LVOT	= left ventricular outflow tract
MDCT	= multidetector computed tomography
NCDR	= National Cardiovascular Data Registry
PARTNER	= Placement of Aortic Transcatheter Valve trial
PH	= pulmonary hypertension
RV	= right ventricular
SOURCE	= SAPIEN Aortic Biosprosthesis European Outcome registry
STS	= Society of Thoracic Surgeons
TAVR	= transcatheter aortic valve replacement
TEE	= transesophageal echocardiogram
TTE	= transthoracic echocardiography
VARC	= Valve Academic Research Consortium

TABLE OF CONTENTS

Preamble	e31
1. Introduction	e32
1.1. Document Development Process	e32
1.1.1. Writing Committee Organization	e32
1.1.2. Document Development and Approval	e32
1.2. Purpose of This Document	e32
2. Background and Historical Aspects	e33
2.1. Pathophysiology and Clinical Course	e33
2.2. Diagnosis	e33
2.2.1. Echocardiography Versus Catheterization	e33
2.2.2. Stress Testing	e34
2.3. Special Considerations	e34
2.3.1. Symptom Status	e34
2.3.2. Associated Coronary Artery Disease	e34
2.3.3. Associated Lesions—AR, MR, Pulmonary Hypertension, TR	e34
2.3.4. Low Gradient—Low EF	e35
2.3.5. Basal Septal Hypertrophy—Outflow Tract Gradients	e35
3. Current Treatment Options	e35
3.1. Surgical AVR	e35
3.1.1. Valve Type	e35
3.1.1.1. Mechanical Valves	e35
3.1.1.2. Bioprosthetic Valves	e35
3.1.2. Procedural Hazards	e36
3.1.3. Patient Selection	e36
3.1.3.1. Use of sts and euroscore Models in Patient Selection for Conventional AVR	e36
3.1.3.2. Patient Risk of AVR	e36
3.1.3.2.1. Specific Surgical Risks	e36
3.1.3.2.1.1. Stroke	e36
3.1.3.2.1.2. Other Complications	e37
3.1.3.3. Prohibitive Risk, Extreme Risk, Inoperability	e37
3.2. Alternatives to AVR	e38
3.2.1. Medical Therapy	e38
3.2.2. Balloon Aortic Valvuloplasty	e38
4. Transcatheter Aortic Valve Replacement	e38
4.1. Background and History	e38
4.2. Device Description	e38
4.3. Current State of the Evidence	e40
4.3.1. Registry Experience	e40
4.3.1.1. Demographics	e41
4.3.1.2. Outcomes	e41
4.3.1.2.1. Procedural Success and Hazards	e41
4.3.1.2.2. Early and Late Morbidity and Mortality	e41
4.3.1.2.3. Quality of Life in Registries	e41
4.3.1.2.4. Learning Curve	e41
4.3.2. Randomized Controlled Trial	e42
4.3.2.1. PARTNER Trial Design	e42
4.3.2.2. Demographics and Other Baseline Characteristics	e43
4.3.2.3. PARTNER Trial Results	e44
4.3.2.3.1. Quality of Life	e45
4.3.2.3.2. Continued-Access Protocol	e45
4.3.2.4. TAVR-Specific Clinical Issues	e46
4.3.2.4.1. Stroke	e46
4.3.2.4.2. Conduction Defects	e47
4.3.2.4.3. Vascular Complications	e47
4.3.2.4.4. Patient Preferences	e47
4.3.2.4.5. Benefit/Risk Assessment	e47
4.3.2.5. Medtronic CoreValve U.S. Pivotal Trial	e48
5. Integration of TAVR Into Clinical Practice	e48
5.1. Patient Evaluation and Management	e48
5.1.1. Multidisciplinary Team	e48
5.1.2. Patient Selection	e49
5.1.2.1. Inclusion/Exclusion Criteria	e49
5.1.2.2. Specific Patient Subsets	e49
5.1.2.2.1. Porcelain Aorta, Friable Aortic Atheroma, Radiation Heart Disease	e49
5.1.2.2.2. Very Elderly	e49
5.1.2.2.3. Frailty and Futility Versus Utility	e49
5.1.3. Care Plan in Candidates for TAVR	e51
5.1.4. Imaging Assessment	e51
5.1.4.1. Echocardiography	e51

Download English Version:

<https://daneshyari.com/en/article/5991522>

Download Persian Version:

<https://daneshyari.com/article/5991522>

[Daneshyari.com](https://daneshyari.com)